RespireRx Pharmaceuticals Inc (RSPI)

[myostrain]

From this am. press release, "Cortex recently initiated additional human clinical trials for CX1739.....Assuming that the current Phase I studies are encouraging, Cortex plans to pursue CX1739 as a potential treatment for Attention Deficit Hyperactivity Disorder in Phase II efficacy trials during the second quarter of 200"

If a RD deal is made soon with liveable upfronts, then maybe good results of the recently initiated clinical trials for CX1739 may provide enough of a SP pop to help with financing at that time if needed.